Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
| Conditionnement | Référence | Disponibilité | Prix |
|---|---|---|---|
| 200 mg | Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit. | 621,00 $ |
A propos de cet article
Formule empirique (notation de Hill) :
C13H18N4O3
Numéro CAS:
Poids moléculaire :
278.31
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
621,00 $
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aidergrade
pharmaceutical primary standard
API family
pentoxifylline
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CN1C=NC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C
InChI
1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8,10-11H,4-7H2,1-3H3
InChI key
MQGNNJQTNFHNHK-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Pentoxifylline USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Pentoxifylline Compounded Oral Suspension
- Pentoxifylline Extended-Release Tablets
Biochem/physiol Actions
Phosphodiesterase inhibitor; inhibits synthesis of tumor necrosis factor α (TNF-α).
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
1 of 1
Cet article | |||
|---|---|---|---|
| manufacturer/tradename USP | manufacturer/tradename EDQM | manufacturer/tradename - | manufacturer/tradename - |
| grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade certified reference material, pharmaceutical secondary standard | grade - |
| format neat | format neat | format - | format - |
| application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) | application(s) pharmaceutical | application(s) - |
| API family pentoxifylline | API family pentoxifylline | API family pentoxifylline | API family - |
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Lact.
Classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Donghao Lv et al.
The Cochrane database of systematic reviews, (3)(3), CD007677-CD007677 (2009-07-10)
Endometriosis is a chronic, recurring condition that occurs during the reproductive years. It is characterized by endometrial tissue developing outside the uterine cavity. This endometrial tissue development is dependent on estrogen produced primarily by the ovaries and, therefore, traditional management
Donghao Lu et al.
The Cochrane database of systematic reviews, 1, CD007677-CD007677 (2012-01-20)
Endometriosis is a chronic, recurring condition that occurs during the reproductive years. It is characterized by endometrial tissue developing outside the uterine cavity. This endometrial tissue development is dependent on oestrogen produced primarily by the ovaries and, therefore, traditional management
Kareem Salhiyyah et al.
The Cochrane database of systematic reviews, 1, CD005262-CD005262 (2012-01-20)
Intermittent claudication (IC) is a symptom of peripheral arterial occlusive disease (PAD). It is associated with high morbidity and mortality. Pentoxifylline is one of many drugs used to treat IC. Pentoxifylline decreases blood viscosity, improves erythrocyte flexibility, and increases microcirculatory flow and tissue
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 1508901-200MG | 04061833860823 |